Updated 02:01 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,868.50 -0.46% CL 85.14 -3.86% BTC 65,305.22 0.00%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,869 −0.46% BTC $65,305 VIX 22.91 +18.70% latest tape · as of 02:01 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic

Evolus Inc

EOLS · NASDAQ · USD · Market cap $377M · 350 employees

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

FAIL · Does not pass the screen
6.96 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price6.96 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.31)
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $8.52 to $9.80, base estimate $8.52 (screen dated 2026-11-13).

Current read
Distribution ?
Undervalued · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.31, read 2026-11-14
  • Ethical does not pass the values gate
Price6.96 USD
Fair value8.52
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-04Read Distribution7.37-5.6% to today ✓Markdown gives way to Distribution after an 8% slide in 5 weeks
2026-10-02Read Markdown7.99-12.9% to today ✓Markup gives way to Markdown after a 39% rise in 5 weeks
2026-08-28Read Markup5.73+21.5% to today ✓Markdown gives way to Markup after a 15% slide in 8 weeks
2026-07-02Read Markdown6.73+3.4% to today First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Evolus Inc holds its Distribution at $6.96. The statistical read favours the sellers, held for 50 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateThe statistical read favours the sellers, held for 50 days
Price at the screen$6.96
ValuationN/A trailing · 33.29 forward price to earnings
Values screenFAIL · score 70.0
Beta1.32
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 68.62% Below 33% Interest-bearing debt is 68.6% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 48.05% Below 49% Money owed to the company is 48.0% of assets, under the 49% limit. Pass
Revenue purity 0.65% Below 5% Only 0.6% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Evolus's business is in a permissible area, but its interest-bearing debt is about 69% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when EOLS's ethical verdict changes

Today EOLS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly an 18% discount to our $8.52 fair value, none competitive moat, 6.70% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

8.52Conservative8.52Base case9.80Growth case 6.96Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 18.3% discount to the base estimate.

The Street's Range
10.00Street low 14.00Street average 20.00Street high 6.96Price

Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +101% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $8.52, with a range of $8.52 to $9.80, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 7%-growth business trading at just 33.3x forward earnings, with a none competitive moat. That is an 18% discount to our $8.52 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 6 analysts rate it Strong Buy with a $14.00 average target, about 101% above the screened price.

The fundamentals · plain-English read
Forward P/E33.3xexpensive even after accounting for its growth
EPS, trailing-0.66
EPS, forward0.24
Revenue growth+6.7%slow but positive growth
Profit margin-14.4%currently unprofitable
FCF yield-6.16%
Current ratio2.04comfortably covers its short-term bills
Beta1.32moves a little more than the market
Short interest, float0.09%
52-week range3.86 - 10.20
MoatNONE
Market cap$377M
Employees350

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

EOLS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Distribution $6.81 -7.6% Entry 11

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-11-04 Distribution · changed $7.37 -1.9% Entry 10

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-10-28 Markdown $7.51 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-10-21 Markdown $7.51 -2.8% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-10-14 Markdown $7.73 -3.3% Entry 7

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-10-02 Markdown · changed $7.99 +39.4% Entry 6

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 39.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15. Since the last review it its composite score eased.

2026-08-28 Markup · changed $5.73 +0.0% Entry 5

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-07-27 Markdown $5.73 -14.9% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-07-18 Markdown $6.73 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 31%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it strong buy, with a mean price target of $15.

2026-07-03 Markdown $6.73 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in EOLS's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.32 +7.4% · $1,074 +7.4%
2 months $4.27 +59.0% · $1,590 +59.0%
3 months $4.91 +38.3% · $1,383 +38.3%
6 months $6.91 -1.7% · $983 -1.7%
1 year $9.87 -31.2% · $688 -31.2%
2 years $11.43 -40.6% · $594 -40.6%
3 years $8.32 -18.4% · $816 -18.4%
5 years $12.33 -44.9% · $551 -44.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever EOLS does next, these words stay.

Evolus Inc · EOLS · Distribution · $6.96
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.